Marshall Wace’s Kindred Biosciences, Inc. KIN Stock Holding History

Marshall Wace’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-5,760	Closed	-$53K	–	2021
2019 Q1	$53K	Buy	+5,760	New	+$58.5K	﹤0.01%	1524

Other funds holding KIN

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace's KIN Position: Q2 2019 in Review

Marshall Wace sold out of Kindred Biosciences, Inc. (KIN) in Q2 2019, closing a stake of 5,760 shares — an estimated $53K sold.

Marshall Wace first reported a position in KIN in Q1 2019 and held it in 1 quarter. The position peaked at $53K in Q1 2019. 75 funds tracked by Wall St. Rank hold KIN as of Q2 2019.

Marshall Wace reported no remaining Kindred Biosciences, Inc. position as of Q2 2019 after selling out during the quarter.
Marshall Wace sold 5,760 Kindred Biosciences, Inc. shares in Q2 2019, an estimated $53K.
Marshall Wace first reported a position in Kindred Biosciences, Inc. in Q1 2019 and held it in 1 quarter.
Marshall Wace's Kindred Biosciences, Inc. position peaked at $53K in Q1 2019.
75 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2019.

Based on Marshall Wace's 13F filing for Q2 2019, filed 14 Aug 2019.